Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Praluent long-term safety extension
NCT03694197Phase 4Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2018
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 4, open-label, single-arm trial of alirocumab in heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Primary endpoint: Number of Participants With Adverse Events up to 80 weeks. Started Sep 2018; status: terminated.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)hypercholesterolemia
Beyond the preview
Go deeper on NCT03694197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03694197.